Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Industry Bids For Boost In Healthtech And Digital Investment

Executive Summary

The UK is relatively well placed in European comparisons regarding access to medtech funding, but it is also ready and waiting for further improvement, say the local venture capital (BVCA) and healthtech industry (ABHI) associations.

You may also be interested in...



Re-Appointed Hancock Puts Shoulder Into UK Digital Health-Care Drive

The UK election result allowed newly-reinstalled prime minister Johnson to tinker with his cabinet. Surviving the small reshuffle was health secretary Matt Hancock, who wasted no time in setting out 2020 plans to support the digitally-enabled NHS of the future.

UK Medtechs Must Face Up To Brexit Certainty After Election Result

The December 12 UK general election returned a Conservative majority, the scale or which few would have predicted. It means that the  new government can press on with its plans for Brexit, the uncertainty now surrounding only when, not if.

UK Plugs Into ‘Golden Period’ For Medtech Innovation

The “what” and the “how” involved in bringing medical technology to market for adoption by health-care systems is changing fast. The UK is laying the groundwork to be a global medtech innovation champion with two new tools: NHS England’s Long Term Plan and the newly boosted Accelerated Access Collaborative. The AAC's first chief executive, Sam Roberts, has been profiling her role in this prospective UK market access transformation.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT126047

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel